CL2009001065A1 - Compuestos derivados de 4-pirimidinil-1,3-tiazol (o 1,3-oxazol) sulfonamidas sustituidas, inhibidores de quinasas raf; composicion farmaceutica; procedimiento de preparacion; y uso para tratar un neoplasma susceptible, seleccionado de adenocarcinoma de barret, carcinomas del tracto biliar y cancer de seno, entre otros. - Google Patents

Compuestos derivados de 4-pirimidinil-1,3-tiazol (o 1,3-oxazol) sulfonamidas sustituidas, inhibidores de quinasas raf; composicion farmaceutica; procedimiento de preparacion; y uso para tratar un neoplasma susceptible, seleccionado de adenocarcinoma de barret, carcinomas del tracto biliar y cancer de seno, entre otros.

Info

Publication number
CL2009001065A1
CL2009001065A1 CL2009001065A CL2009001065A CL2009001065A1 CL 2009001065 A1 CL2009001065 A1 CL 2009001065A1 CL 2009001065 A CL2009001065 A CL 2009001065A CL 2009001065 A CL2009001065 A CL 2009001065A CL 2009001065 A1 CL2009001065 A1 CL 2009001065A1
Authority
CL
Chile
Prior art keywords
pyrimidinyl
sulfonamides
barret
carcinomas
adenocarcinoma
Prior art date
Application number
CL2009001065A
Other languages
English (en)
Inventor
Xinrong Tian
Kevin Kuntz
Tara Renae Rheault
Scott Howard Dickerson
Kimberly Petrov
Gregory Schaaf
John Stellwagen
David Edward Uehling
Alex Gregory Waterson
Brian Wilson
Jerry Leroy Adams
Neil W Johnson
Jeffrey M Ralph
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41265326&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2009001065(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of CL2009001065A1 publication Critical patent/CL2009001065A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Compuestos derivados de 4-pirimidinil-1,3-tiazol sulfonamidas o 4-pirimidinil-1,3-oxazol sulfonamidas sustituidas; composición farmacéutica que los comprende; proceso para prepararlos; y su uso para tratar un neoplasma susceptible seleccionado de adenocarcinoma de barret, carcinomas del tracto biliar y cáncer de seno, entre otros.
CL2009001065A 2008-05-06 2009-05-04 Compuestos derivados de 4-pirimidinil-1,3-tiazol (o 1,3-oxazol) sulfonamidas sustituidas, inhibidores de quinasas raf; composicion farmaceutica; procedimiento de preparacion; y uso para tratar un neoplasma susceptible, seleccionado de adenocarcinoma de barret, carcinomas del tracto biliar y cancer de seno, entre otros. CL2009001065A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5074408P 2008-05-06 2008-05-06

Publications (1)

Publication Number Publication Date
CL2009001065A1 true CL2009001065A1 (es) 2010-12-31

Family

ID=41265326

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2009001065A CL2009001065A1 (es) 2008-05-06 2009-05-04 Compuestos derivados de 4-pirimidinil-1,3-tiazol (o 1,3-oxazol) sulfonamidas sustituidas, inhibidores de quinasas raf; composicion farmaceutica; procedimiento de preparacion; y uso para tratar un neoplasma susceptible, seleccionado de adenocarcinoma de barret, carcinomas del tracto biliar y cancer de seno, entre otros.

Country Status (34)

Country Link
US (6) US7994185B2 (es)
EP (2) EP2282636B1 (es)
JP (1) JP5426664B2 (es)
KR (1) KR101628746B1 (es)
CN (1) CN102083312B (es)
AR (1) AR071617A1 (es)
AU (1) AU2009244491B2 (es)
BR (1) BRPI0912541B8 (es)
CA (1) CA2723396C (es)
CL (1) CL2009001065A1 (es)
CO (1) CO6321189A2 (es)
CY (1) CY1117615T1 (es)
DK (1) DK2282636T3 (es)
DO (1) DOP2010000326A (es)
EA (1) EA019349B1 (es)
ES (1) ES2576684T3 (es)
HR (1) HRP20160447T1 (es)
HU (1) HUE028820T2 (es)
IL (1) IL209018A (es)
JO (1) JO3408B1 (es)
MA (1) MA32369B1 (es)
MX (1) MX2010012074A (es)
MY (1) MY155317A (es)
NZ (1) NZ588970A (es)
PE (1) PE20091952A1 (es)
PL (1) PL2282636T3 (es)
RS (1) RS54725B1 (es)
SG (1) SG190624A1 (es)
SI (1) SI2282636T1 (es)
TW (1) TWI432430B (es)
UA (1) UA103319C2 (es)
UY (1) UY31806A (es)
WO (1) WO2009137391A2 (es)
ZA (1) ZA201007960B (es)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
WO2009012283A1 (en) 2007-07-17 2009-01-22 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
KR20100122505A (ko) * 2008-02-29 2010-11-22 어레이 바이오파마 인크. Ｒａｆ 저해물질 화합물 및 이들의 이용 방법
JP2011513332A (ja) * 2008-02-29 2011-04-28 アレイ バイオファーマ、インコーポレイテッド 癌の治療のためのｒａｆ阻害剤としてのｎ−（６−アミノピリジン−３−イル）−３−（スルホンアミド）ベンズアミド誘導体
JP2011513331A (ja) * 2008-02-29 2011-04-28 アレイ バイオファーマ、インコーポレイテッド ピラゾール［３，４−ｂ］ピリジンＲＡＦ阻害剤
CA2716947A1 (en) * 2008-02-29 2009-09-11 Array Biopharma Inc. Imidazo [4,5-b] pyridine derivatives used as raf inhibitors
UA103319C2 (en) * 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
US20110319392A1 (en) * 2009-03-12 2011-12-29 George Adjabeng Thiazole Sulfonamide And Oxazole Sulfonamide Kinase Inhibitors
MY172424A (en) 2009-04-03 2019-11-25 Hoffmann La Roche Propane- i-sulfonic acid {3- (4-chloro-phenyl)-1h-pyrrolo [2, 3-b] pyridine-3-carconyl] -2, 4-difluoro-phenyl} -amide compositions and uses thereof
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
US8242260B2 (en) * 2009-08-28 2012-08-14 Novartis Ag Compounds and compositions as protein kinase inhibitors
AR077975A1 (es) 2009-08-28 2011-10-05 Irm Llc Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
JP2013507382A (ja) 2009-10-08 2013-03-04 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 組合せ
MX2012004140A (es) * 2009-10-08 2012-09-07 Glaxosmithkline Llc Combinacion.
EP2488184A4 (en) * 2009-10-12 2013-04-24 Glaxosmithkline Llc COMBINATION
HUE067723T2 (hu) * 2009-10-16 2024-11-28 Novartis Ag MEK-inhibitort és B-Raf-inhibitort tartalmazó kombináció
CN106220623A (zh) 2009-11-06 2016-12-14 普莱希科公司 用于激酶调节的化合物和方法及其适应症
EP2498608A4 (en) * 2009-11-10 2013-04-24 Glaxosmithkline Llc BENZOLSULFONAMIDE THIAZOL AND OXAZOLE COMPOUNDS
CN104958294A (zh) * 2010-01-27 2015-10-07 内尔维安诺医学科学有限公司 作为蛋白激酶抑制剂的3,4-二芳基吡唑的亚磺酰氨基衍生物
JP2013529619A (ja) * 2010-06-25 2013-07-22 ノバルティス アーゲー タンパク質キナーゼ阻害剤としてのヘテロアリール化合物および組成物
EP2601185B1 (en) * 2010-08-03 2015-10-07 Nerviano Medical Sciences S.r.l. Derivatives of pyrazolophenyl-benzenesulfonamide compounds and use thereof as antitumor agents
EP2616057A4 (en) * 2010-09-14 2014-03-12 Glaxosmithkline Ip No 2 Ltd COMBINATION OF B-RAF AND VEGFR INHIBITORS
WO2012061683A2 (en) * 2010-11-05 2012-05-10 Glaxosmithkline Llc Methods for treating cancer
AU2011329666A1 (en) * 2010-11-19 2013-05-30 Glaxosmithkline Intellectual Property (No.2) Limited Method of treatment with BRaf inhibitor
TWI505828B (zh) 2010-12-20 2015-11-01 葛蘭素史克智慧財產（第二）有限公司 新穎醫藥組成物
EP2668180B1 (en) * 2011-01-25 2018-08-01 The Regents of The University of Michigan Bcl-2/bcl-xl inhibitors for use in the treatment of cancer
US9624213B2 (en) 2011-02-07 2017-04-18 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
AR085279A1 (es) 2011-02-21 2013-09-18 Plexxikon Inc Formas solidas de {3-[5-(4-cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico
CN103403002B (zh) * 2011-02-24 2016-06-22 内尔维阿诺医学科学有限公司 作为激酶抑制剂的噻唑基苯基-苯磺酰氨基衍生物
WO2013019620A2 (en) * 2011-07-29 2013-02-07 Glaxosmithkline Llc Method of treating cancer using combination of braf inhibitor, mek inhibitor, and anti-ctla-4 antibody
US8389723B1 (en) * 2011-08-24 2013-03-05 Glaxosmithkline Llc Deuterated benzene sulfonamide thiazole compounds
RU2622015C2 (ru) 2011-11-11 2017-06-08 Новартис Аг Способ лечения пролиферативного заболевания
SI2782557T1 (sl) 2011-11-23 2019-02-28 Array Biopharma, Inc., Farmacevtske formulacije
US20130184280A1 (en) * 2011-12-21 2013-07-18 Telik, Inc. Substituted thiazoles as vegfr2 kinase inhibitors
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
KR20190057421A (ko) 2012-08-17 2019-05-28 에프. 호프만-라 로슈 아게 코비메티닙 및 베무라피닙을 투여함을 포함하는 흑색종의 조합 치료법
CN104582706A (zh) 2012-09-04 2015-04-29 葛兰素史克有限责任公司 辅助癌症治疗的方法
WO2014066606A2 (en) * 2012-10-25 2014-05-01 Glaxosmithkline Llc Combination
WO2014072486A1 (en) * 2012-11-09 2014-05-15 INSERM (Institut National de la Santé et de la Recherche Médicale) New benzene sulfonamide thiazole compounds
CN103936728B (zh) * 2013-01-18 2016-08-10 通化济达医药有限公司 噻唑激酶抑制剂
CN103936730A (zh) * 2013-01-22 2014-07-23 通化济达医药有限公司 苯磺酰胺噻唑激酶抑制剂
CN103965170A (zh) * 2013-01-24 2014-08-06 通化济达医药有限公司 苯磺酰胺吡唑激酶抑制剂
CN103965180B (zh) * 2013-01-24 2016-09-07 通化济达医药有限公司 苯磺酰胺噁唑和噻唑激酶抑制剂
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
CN104109159A (zh) * 2013-04-17 2014-10-22 杭州普晒医药科技有限公司 苯磺酰胺噻唑化合物的新晶型及其制备方法
TWI634114B (zh) * 2013-05-08 2018-09-01 永恒生物科技公司 作為激酶抑制劑之呋喃酮化合物
CN105228983A (zh) 2013-05-30 2016-01-06 普莱希科公司 用于激酶调节的化合物及其适应症
TN2015000444A1 (en) 2013-06-03 2017-04-06 Novartis Ag Combinations of an anti-pd-l1 antibody and a mek inhibitor and/or a braf inhibitor
WO2015003571A1 (zh) 2013-07-08 2015-01-15 杭州普晒医药科技有限公司 达拉菲尼甲磺酸盐的新晶型及其制备方法
WO2015059677A1 (en) 2013-10-26 2015-04-30 Glaxosmithkline Intellectual Property (No.2) Limited Methods of treating cancer
CN103588767B (zh) * 2013-11-20 2016-01-20 苏州明锐医药科技有限公司 达拉菲尼的制备方法
CN103880831A (zh) * 2013-11-25 2014-06-25 镇江圣安医药有限公司 N-(2-氟苯基)-2,6-二氟苯磺酰胺的衍生物及其应用
EP3079698A1 (en) 2013-12-12 2016-10-19 Novartis AG Combinations of trametinib, panitumumab and dabrafenib for the treatment of cancer
ES2660989T3 (es) 2013-12-28 2018-03-27 Guardant Health, Inc. Métodos y sistemas para detectar variantes genéticas
WO2015105822A1 (en) * 2014-01-07 2015-07-16 Glaxosmithkline Llc Cancer treatment method
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
CN107074828B (zh) * 2014-09-12 2020-05-19 诺华股份有限公司 用作raf激酶抑制剂的化合物和组合物
WO2016059548A1 (en) * 2014-10-13 2016-04-21 Mylan Laboratories Ltd Processes for the preparation of dabrafenib
CN105651927B (zh) * 2014-11-14 2019-12-13 泰州复旦张江药业有限公司 一种伐地昔布/帕瑞昔布有关物质的rt-hplc检测方法
PL3277272T3 (pl) 2015-03-31 2022-01-24 Syros Pharmaceuticals, Inc. Sposoby stratyfikacji pacjentów do leczenia agonistami receptora kwasu retinowego
CN106366080A (zh) * 2015-07-21 2017-02-01 重庆大学 一种抗黑色素瘤的化合物及其应用
EP3355886A1 (en) * 2015-08-28 2018-08-08 Novartis AG Pharmaceutical combination comprising the pi3k inhibitor alpelisib and the b-raf inhibitor dabrafenib; the use of such combination in the treatment or prevention of cancer
EP3340987A1 (en) 2015-08-28 2018-07-04 Novartis AG Combination of ribociclib and dabrafenib for treating or preventing cancer
US9868994B2 (en) 2016-04-08 2018-01-16 Syros Pharmaceuticals, Inc. Methods of stratifying patients for treatment with retinoic acid receptor-α agonists
AU2017329090B9 (en) 2016-09-19 2019-09-05 Novartis Ag Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor
US20190263796A1 (en) 2016-09-23 2019-08-29 Cellipse Lim kinase inhibitors, pharmaceutical composition and method of use in limk-mediated diseases
US20180125812A1 (en) 2016-11-04 2018-05-10 Emory University Dehydroacetic Acid (DHAA) and Derivative for Uses in Treating Cancer
WO2018146253A1 (en) 2017-02-10 2018-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the mapk pathway
CA3057969A1 (en) 2017-05-02 2018-11-08 Novartis Ag Combination therapy
JP2019529343A (ja) 2017-07-05 2019-10-17 ノバルティス アーゲー 新規な医薬組成物
WO2019133810A1 (en) 2017-12-28 2019-07-04 Tract Pharmaceuticals, Inc. Stem cell culture systems for columnar epithelial stem cells, and uses related thereto
CN108129471A (zh) * 2018-03-20 2018-06-08 韩邦森 一种噻唑取代嘧啶类化合物的合成工艺
MX2020010231A (es) 2018-03-30 2020-10-28 Novartis Ag Una combinacion farmaceutica triple que comprende dabrafenib, trametinib y un inhibidor de erk.
EP3560516A1 (en) 2018-04-27 2019-10-30 Bergen Teknologioverforing AS Combination therapy including beta-sitosterol in combination with at least one of a braf inhibitor, a mek inhibitor or an erk inhibitor and methods and use thereof
WO2019246121A1 (en) * 2018-06-18 2019-12-26 Duke University Compositions and methods for treating disorders characterized with aberrant ras/mapk signaling
JP2022504905A (ja) 2018-10-16 2022-01-13 ノバルティス アーゲー 標的化療法に対する応答を予測するためのバイオマーカーとしての単独の又は免疫マーカーと組み合わせた腫瘍突然変異負荷
WO2020124397A1 (en) * 2018-12-19 2020-06-25 Inventisbio Shanghai Ltd. C-terminal src kinase inhibitors
US20220040324A1 (en) 2018-12-21 2022-02-10 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and kinase inhibitor
GB201901507D0 (en) 2019-02-04 2019-03-27 St Georges Hospital Medical School New treatment
EP3969449B1 (en) 2019-05-13 2025-02-12 Novartis AG New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
EP4069692A1 (en) * 2019-12-05 2022-10-12 Institut National de la Santé et de la Recherche Médicale (INSERM) N-(3-(5-(pyrimidin-4-yl)thiazol-4-yl)phenyl)sulfonamide compounds and their uses as braf inhibitors
CN118767143A (zh) 2019-12-12 2024-10-15 听治疗有限责任公司 用于预防和治疗听力损失的组合物和方法
EP4110341A2 (en) 2020-02-28 2023-01-04 Novartis AG A triple pharmaceutical combination comprising dabrafenib, an erk inhibitor and a raf inhibitor
EP4110338A1 (en) 2020-02-28 2023-01-04 Novartis AG A triple pharmaceutical combination comprising dabrafenib, an erk inhibitor and a shp2 inhibitor
CN115443274B (zh) * 2020-04-30 2025-04-25 勤浩医药（苏州）有限公司 含苯基并内磺酰胺的化合物
NZ801119A (en) * 2020-12-02 2026-02-27 Neupharma Inc Certain chemical entities, compositions, and methods
CN112724052B (zh) * 2021-01-21 2021-09-07 南京艾美斐生物医药科技有限公司 一种gpr101蛋白受体抑制剂及其制备和应用
CN113024384A (zh) * 2021-03-16 2021-06-25 湖南工程学院 一种2-氟-3-硝基苯甲酸中间体原料的合成方法
US20240310266A1 (en) 2021-03-18 2024-09-19 Novartis Ag Biomarkers for cancer and methods of use thereof
WO2022259157A1 (en) 2021-06-09 2022-12-15 Novartis Ag A triple pharmaceutical combination comprising dabrafenib, trametinib and a shp2 inhibitor
CN113717053B (zh) * 2021-09-02 2023-10-27 合肥利夫生物科技有限公司 一种酪氨酸激酶抑制剂关键中间体的合成方法
WO2023070076A1 (en) * 2021-10-22 2023-04-27 The Board Of Trustees Of The University Of Illinois Compounds for cancers driven by braf mutation
CN119053595A (zh) * 2022-03-28 2024-11-29 尼坎治疗公司 作为细胞周期蛋白依赖性激酶2抑制剂的磺酰氨基衍生物
CN119790053A (zh) * 2022-06-08 2025-04-08 霖康疗法公司 作为细胞周期蛋白依赖性激酶2抑制剂的磺酰胺衍生物
CN115260179A (zh) * 2022-08-23 2022-11-01 江苏大学 一种2-氨基嘧啶衍生物及其制备方法和应用
WO2024084086A1 (en) * 2022-10-20 2024-04-25 Biper Therapeutics Sas Compositions comprising a benzene sulfonamide thiazole compound
CN115925630B (zh) * 2022-12-15 2025-03-25 金仓(上海)医药生物科技有限公司 一种吡唑硫代酰胺的制备方法
WO2024189184A1 (en) 2023-03-16 2024-09-19 Hua Huang N-[3-(5-(2-aminopyrimidin-4-yl)-2-(tert-butyl)thiazol-4-yl)-2-fluorophenyl]-2,6-difluorobenzenesulfonamide or a pharmaceutically acceptable salt thereof for use in the treatment and/or prevention of cerebral cavernous malformation
AU2023439518A1 (en) 2023-04-06 2025-08-28 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumors
CN119490423A (zh) * 2023-08-15 2025-02-21 沈阳中化农药化工研发有限公司 一种制备2-氟-3-氨基苯甲酸及其酯类化合物的方法
WO2025072462A1 (en) * 2023-09-27 2025-04-03 Nikang Therapeutics, Inc. Sulfonamide derivatives as cyclin-dependent kinase 2 inhibitors
WO2025132388A2 (en) 2023-12-21 2025-06-26 Synthon B.V A process for making dabrafenib
WO2025253311A1 (en) 2024-06-04 2025-12-11 Hetero Labs Limited 1,2-dicarboxamide compounds as kinase inhibitors
WO2026074526A1 (en) 2024-10-04 2026-04-09 Hetero Labs Limited 1,2-dicarboxamide compounds as kinase inhibitors
CN120393011A (zh) * 2025-04-14 2025-08-01 武汉大学人民医院（湖北省人民医院） Smoc2的诊断和制药用途

Family Cites Families (207)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9015764D0 (en) 1990-07-18 1990-09-05 Fujisawa Pharmaceutical Co Pyrazolopyridine compound and processes for preparation thereof
KR970069028A (ko) 1996-04-01 1997-11-07 김은영 화학색전용 에멀젼의 제조방법
CA2249665A1 (en) 1996-04-03 1997-10-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1997036898A1 (en) 1996-04-03 1997-10-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1997036876A1 (en) 1996-04-03 1997-10-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
AU721952B2 (en) 1996-04-03 2000-07-20 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1997036585A1 (en) 1996-04-03 1997-10-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
AU716381B2 (en) 1996-04-03 2000-02-24 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
GB9609441D0 (en) 1996-05-04 1996-07-10 Zeneca Ltd Process
WO1998000134A1 (en) 1996-06-28 1998-01-08 Merck & Co., Inc. Fibrinogen receptor antagonists
US5755056A (en) 1996-07-15 1998-05-26 Remington Arms Company, Inc. Electronic firearm and process for controlling an electronic firearm
US5877193A (en) * 1996-07-19 1999-03-02 Hoffmann-La Roche Inc. Use of N-(4-aryl-thiazol-2-yl)-sulfonamides
DZ2376A1 (fr) 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
EP0977892A1 (en) 1997-04-24 2000-02-09 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods and compositions for use in modulating expression of matrix metalloproteinase genes
DK1032575T3 (da) * 1997-09-05 2003-10-20 Glaxo Group Ltd 2,3-diaryl-pyrazol(1,5-b)pyridazinderivater, deres fremstilling og anvendelse som cyclooxygenase 2 (COX-2) inhibitor
KR100643419B1 (ko) * 1998-03-27 2006-11-10 얀센 파마슈티카 엔.브이. Ｈｉｖ를 억제하는 피리미딘 유도체
US6294558B1 (en) * 1999-05-31 2001-09-25 Pfizer Inc. Sulfonylbenzene compounds as anti-inflammatory/analgesic agents
GB9812768D0 (en) 1998-06-13 1998-08-12 Zeneca Ltd Methods
HUP0104202A3 (en) 1998-10-22 2003-12-29 Hoffmann La Roche Thiazole-derivatives, process for their preparation and pharmaceutical compositions containing them
US7223772B1 (en) 1998-11-03 2007-05-29 Smithkline Beecham Corporation Pyrazolopyridine derivatives as selective cox-2 inhibitors
CA2349832A1 (en) * 1999-01-13 2000-07-20 Warner-Lambert Company Benzenesulfonamide derivatives and their use as mek inhibitors
FR2788770B1 (fr) 1999-01-21 2001-02-16 Oreal Nouveaux 2-sulfonylaminophenols cationiques, leur utilisation a titre de coupleur pour la teinture d'oxydation, compositions les comprenant et procedes de teinture
ATE261444T1 (de) 1999-02-27 2004-03-15 Glaxo Group Ltd Pyrazolopyridine
GB9904930D0 (en) * 1999-03-04 1999-04-28 Glaxo Group Ltd Thiazoloindolinone compounds
EP1173254A2 (en) 1999-04-27 2002-01-23 Smithkline Beecham Plc Novel treatment of neurotraumatic conditions with a raf inhibitor
UA71971C2 (en) 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
KR20020063837A (ko) 1999-07-19 2002-08-05 시오노기세이야쿠가부시키가이샤 아실옥시메톡시카르보닐 측쇄를 갖는 삼환 화합물
BR0012697A (pt) 1999-07-23 2002-04-09 Shionogi & Co Inibidores da diferenciação de th2
WO2001007401A1 (en) 1999-07-23 2001-02-01 Shionogi & Co., Ltd. Tricyclic compounds and drug compositions containing the same
ES2316383T3 (es) 1999-09-17 2009-04-16 Millennium Pharmaceuticals, Inc. Benzamidas e inhibidores relacionados del factor xa.
CZ2002959A3 (cs) 1999-09-17 2002-07-17 Millennium Pharmaceuticals, Inc. Inhibitory faktoru Xa
US6632815B2 (en) 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
AU7922900A (en) 1999-10-27 2001-05-08 Novartis Ag Thiazole and imidazo (4,5-b) pyridine compounds and their pharmaceutical use
AU1529901A (en) * 1999-11-22 2001-06-04 Smithkline Beecham Plc Compounds
WO2001056989A2 (en) 2000-02-01 2001-08-09 Cor Therapeutics, Inc. Inhibitors of factor xa
WO2001064642A2 (en) 2000-02-29 2001-09-07 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
CN100355751C (zh) 2000-03-29 2007-12-19 西克拉塞尔有限公司 2－取代的4－杂芳基－嘧啶、其组合物及其用途
KR20030009416A (ko) 2000-04-04 2003-01-29 시오노기세이야쿠가부시키가이샤 고지용성 약물을 함유하는 유성 조성물
AU2001244610A1 (en) 2000-04-05 2001-10-23 Shionogi And Co., Ltd. Oil-in-water microemulsions containing tricyclic compounds or preconcentrates thereof
US6727267B2 (en) 2000-04-05 2004-04-27 Tularik Inc. NS5B HVC polymerase inhibitors
AU2001259242A1 (en) 2000-04-28 2001-11-12 Glaxo Group Limited Process for the preparation of chemical compounds
AU2001256765A1 (en) 2000-05-16 2001-11-26 Nippon Soda Co., Ltd. Phenyloxazole compounds and fungicides for agricultural and horticultural use
JP2004503527A (ja) 2000-06-13 2004-02-05 イーライ・リリー・アンド・カンパニー スルホンアミド誘導体
WO2002000647A1 (en) 2000-06-23 2002-01-03 Bristol-Myers Squibb Pharma Company Heteroaryl-phenyl substituted factor xa inhibitors
PE20020506A1 (es) 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
US20040067938A1 (en) 2000-09-29 2004-04-08 Penglie Zhang Quaternary amines and related inhibitors of factor xa
ATE301653T1 (de) 2000-12-15 2005-08-15 Glaxo Group Ltd Pyrazolopyridine
JP2004515550A (ja) 2000-12-15 2004-05-27 グラクソ グループ リミテッド 治療用化合物
AU2002232919A1 (en) 2000-12-29 2002-07-16 Alteon, Inc. Method for treating fibrotic diseases or other indications
US7199124B2 (en) 2001-02-02 2007-04-03 Takeda Pharmaceutical Company Limited JNK inhibitor
WO2002070469A2 (en) 2001-03-05 2002-09-12 Icos Corporation Selective pde3b inhibitors and use of the same in therapy
WO2002072581A2 (en) 2001-03-08 2002-09-19 Smithkline Beecham Corporation Pyrazolopyriadine derivatives
WO2002078700A1 (en) 2001-03-30 2002-10-10 Smithkline Beecham Corporation Pyralopyridines, process for their preparation and use as therapteutic compounds
WO2002078701A1 (en) 2001-03-30 2002-10-10 Smithkline Beecham Corporation Use of pyrazolopyridines as therapeutic compounds
ES2266487T3 (es) 2001-04-10 2007-03-01 Smithkline Beecham Corporation Compuestos de pirazolopirina antivirales.
CZ20032829A3 (cs) 2001-04-16 2005-03-16 Tanabe Seiyaku Co., Ltd. Heterocyklické sloučeniny
ATE296826T1 (de) 2001-04-27 2005-06-15 Smithkline Beecham Corp Pyrazolo(1,5)pyridinderivate
AU2002312348A1 (en) 2001-06-06 2002-12-16 Agouron Pharmaceuticals, Inc. Non-peptide gnrh agents, pharmaceutical compositions and methods for their uses, and processes for preparing them
ATE337316T1 (de) 2001-06-21 2006-09-15 Smithkline Beecham Corp Imidazo 1,2-aöpyridin-derivate zur prophylaxe und behandlung von herpes-infektionen
AUPR738301A0 (en) 2001-08-30 2001-09-20 Starpharma Limited Chemotherapeutic agents
WO2003022832A1 (en) 2001-09-05 2003-03-20 Smithkline Beecham P.L.C. Pyridylfurans and pyrroles as raf kinase inhibitors
US20040214834A1 (en) 2001-09-07 2004-10-28 Kristjan Gudmunsson Pyrazolo-pyridines for the treatment of herpes infections
GB0123589D0 (en) 2001-10-01 2001-11-21 Syngenta Participations Ag Organic compounds
EP1432712B1 (en) 2001-10-05 2006-05-17 SmithKline Beecham Corporation Imidazo-pyridine derivatives for use in the treatment of herpes viral infection
DE10154125A1 (de) 2001-10-25 2003-05-22 Zeiss Carl Semiconductor Mfg Messverfahren und Messsystem zur Vermessung der Abbildungsqualität eines optischen Abbildunsgssystems
WO2003047523A2 (en) * 2001-12-04 2003-06-12 Onyx Pharmaceuticals, Inc. Raf-mek-erk pathway inhibitors to treat cancer
JP2005516916A (ja) 2001-12-11 2005-06-09 スミスクライン ビーチャム コーポレーション 抗ヘルペス薬としてのピラゾロ−ピリジン誘導体
WO2004087941A1 (en) 2002-02-15 2004-10-14 The General Hospital Corporation Map-kinase inhibitors as regulators of tumor-associated antigen expression
DE60301339T2 (de) 2002-03-07 2006-03-09 Smithkline Beecham Corp. Pyrazolopyrimidin- und pyrazolotriazinderivate und diese enthaltende pharmazeutische zubereitungen
GB0205693D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
AR039241A1 (es) 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
JP2005529889A (ja) 2002-04-26 2005-10-06 ファイザー・プロダクツ・インク ピリミジン−２，４，６−トリオンメタロ−プロテイナーゼ阻害剤
NI200300045A (es) 2002-04-26 2005-07-08 Pfizer Prod Inc Inhibidores de triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa.
JP2005529919A (ja) 2002-05-10 2005-10-06 スミスクライン ビーチャム コーポレーション 治療用化合物
AU2003249369A1 (en) 2002-06-21 2004-01-06 Cellular Genomics, Inc. Certain amino-substituted monocycles as kinase modulators
BR0313160A (pt) 2002-08-08 2005-07-12 Smithkline Beecham Corp Composto, composição farmacêutica, métodos para tratar uma condição e um neoplasmo suscetìvel em um animal em um animal, processo para preparar um composto e uso de um composto
US20050277118A1 (en) 2002-09-11 2005-12-15 Roth Richard B Methods for identifying subjects at risk of melanoma and treatments thereof
EP1575417A4 (en) 2002-09-30 2007-07-04 Bayer Pharmaceuticals Corp CANCER FORECASTING AND PROGNOSTIC TECHNIQUES AND SURVEILLANCE OF ANTICANCER THERAPY
US20040157836A1 (en) * 2002-10-08 2004-08-12 Comess Kenneth M. Sulfonamides having antiangiogenic and anticancer activity
AU2003295408A1 (en) 2002-11-06 2004-06-03 Smithkline Beecham Corporation Sulfonamides
SE0203754D0 (sv) 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
WO2004058713A1 (en) 2002-12-20 2004-07-15 Irm Llc Differential tumor cytotoxocity compounds and compositions
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
US6893159B1 (en) 2003-01-27 2005-05-17 Christopher Eugene Hosmer Lubrication free connection
WO2004078114A2 (en) 2003-02-28 2004-09-16 Encysive Pharmaceuticals Inc. Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-ii receptor antagonists.
US8178570B2 (en) 2003-04-09 2012-05-15 Exelixis, Inc. Tie-2 modulators and methods of use
US20070099250A1 (en) 2003-04-14 2007-05-03 Ping Hu Methods for treating proliferative diseases and for monitoring the effectiveness of treatment of proliferative diseases
EA200501607A1 (ru) 2003-04-14 2006-06-30 ДЗЕ ИНСТИТЬЮТС ФОР ФАРМАСЬЮТИКАЛ ДИСКАВЕРИ, ЭлЭлСи Замещённые фенилалкановые кислоты
EP1622886A2 (en) 2003-04-30 2006-02-08 The Institutes for Pharmaceutical Discovery, LLC Substituted amino carboxylic acids as inhibitors of protein tyrosine phosphatase-1b
KR20060006954A (ko) 2003-04-30 2006-01-20 디 인스티튜트스 포 파마슈티컬 디스커버리, 엘엘씨 단백질 티로신 포스파타제-１ｂ 억제제로서의 페닐 치환된카르복실산
US7329680B2 (en) 2003-04-30 2008-02-12 The Institute For Pharmaceutical Discovery, Llc Heterocycle substituted carboxylic acids
BRPI0409914A (pt) 2003-04-30 2006-04-25 Inst For Pharm Discovery Inc ácidos carboxìlicos substituìdos
SE0301650D0 (sv) 2003-06-04 2003-06-04 Astrazeneca Ab Novel compounds
BRPI0411275A (pt) 2003-06-10 2006-08-01 Kalypsys Inc compostos de carbonila como inibidores de histona deacetilase para tratamento de doenças; composição farmacêutica; método de modular a atividade catalìtica de hdac; método de tratar doença em um indivìduo; utilização de um composto ou composição; método de inibir hdac
GB0315111D0 (en) 2003-06-27 2003-07-30 Cancer Rec Tech Ltd Substituted 5-membered ring compounds and their use
GB0315517D0 (en) 2003-07-02 2003-08-06 Barrett Kevin J Earth clamp
WO2005007090A2 (en) 2003-07-03 2005-01-27 President And Fellows Of Harvard College Inhibitors of the map kinase pathway
JP2007500178A (ja) 2003-07-30 2007-01-11 サイクラセル・リミテッド プロテインキナーゼ阻害剤としてのピリジニルアミノ−ピリミジン誘導体
WO2005047542A1 (en) 2003-10-16 2005-05-26 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Treatments for inhibiting development and progression of nevi and melanoma having braf mutations
JP5164380B2 (ja) 2003-10-21 2013-03-21 サイクラセル リミテッド ピリミジン−４−イル−３，４−チオン化合物及び治療におけるその使用
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
WO2005070900A1 (en) 2004-01-22 2005-08-04 Altana Pharma Ag N-4-(6- (heteo) aryl-pyrimidin-4-ylaminophenyl) -bezenesulfonamides as kinase inhibitors
CA2554925A1 (en) 2004-01-30 2005-08-11 Ab Science 2-(3-substituted-aryl)amino-4-aryl-thiazoles as tyrosine kinase inhibitors
US8193389B2 (en) 2004-03-11 2012-06-05 Elan Pharmaceuticals, Inc. N-substituted benzene sulfonamides
WO2005087236A1 (en) 2004-03-11 2005-09-22 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
BRPI0508970A (pt) 2004-03-19 2007-08-21 Penn State Res Found método combinatórios e composições para o tratamento de melanoma
DE102004018198A1 (de) * 2004-04-15 2005-11-03 Merck Patent Gmbh Sulfonamide
US20050267032A1 (en) 2004-05-21 2005-12-01 Icagen, Inc. Sulfone-containing prodrugs
GB0411791D0 (en) 2004-05-26 2004-06-30 Cyclacel Ltd Compounds
SI1761528T1 (sl) 2004-06-11 2008-06-30 Japan Tobacco Inc 5-amino-2,4,7-triokso-3,4,7,8-tetrahidro-2H-pirido(2,3-D)pirimidinski derivati in sorodne spojine za zdravljenje raka
JP2007223903A (ja) 2004-07-09 2007-09-06 Takeda Chem Ind Ltd 新規な固体分散体およびその製造方法
PE20060574A1 (es) * 2004-07-28 2006-06-24 Glaxo Group Ltd Derivados de arilpiperazina sulfonamida como agonistas de los receptores de secretagogos de la hormona del crecimiento (ghs)
CA2575466A1 (en) 2004-08-13 2006-02-23 Genentech, Inc. Thiazole based inhibitors of atp-utilizing enzymes
AU2005280167A1 (en) 2004-08-31 2006-03-09 Biogen Idec Ma Inc. Pyrimidinylpyrazoles as TGF-beta inhibitors
GB0420424D0 (en) 2004-09-14 2004-10-20 Ionix Pharmaceuticals Ltd Therapeutic compounds
JP4810814B2 (ja) 2004-09-15 2011-11-09 オムロン株式会社 光学シート及び面光源装置
JP2008514608A (ja) 2004-09-24 2008-05-08 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ スルホンアミド化合物
EP1640018A1 (en) 2004-09-24 2006-03-29 Universität Zürich Combinational therapy for treating cancer
AU2005295734A1 (en) 2004-10-15 2006-04-27 Biogen Idec Ma Inc. Methods of treating vascular injuries
CA2584794A1 (en) 2004-10-26 2006-05-04 Third-Order Nanotechnologies, Inc. Tricyclic spacer systems for nonlinear optical devices
EP1805136A1 (en) 2004-10-28 2007-07-11 The Institutes for Pharmaceutical Discovery, LLC Substituted phenylalkanoic acids
AU2005302409A1 (en) * 2004-10-28 2006-05-11 The Institutes For Pharmaceutical Discovery Llc Substituted carboxylic acids
US20060134068A1 (en) * 2004-11-09 2006-06-22 Mount Sinai School Of Medicine Of New York University Treatment of cancer by simultaneous inhibiton of BRAF and restoration or mimicry of p16INK4A activity
US7713998B2 (en) 2004-11-10 2010-05-11 Ono Pharmaceutical Co., Ltd. Nitrogenous heterocyclic compound and pharmaceutical use thereof
WO2006055503A2 (en) 2004-11-15 2006-05-26 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
WO2006055553A2 (en) 2004-11-15 2006-05-26 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
JP2008520693A (ja) 2004-11-18 2008-06-19 ジ インスチチュート フォー ファーマシューティカル ディスカバリー、エルエルシー プロテインチロシンホスファターゼ阻害剤としての置換アミノ酸
JP2008520692A (ja) 2004-11-18 2008-06-19 ジ インスチチュート フォー ファーマシューティカル ディスカバリー、エルエルシー 複素環置換カルボン酸
EP1836182A2 (en) 2004-11-18 2007-09-26 The Institutes for Pharmaceutical Discovery, LLC Heterocyclylbiphenyl derivates as protein tyrosine phosphatase inhibitors
WO2006064375A2 (en) 2004-12-16 2006-06-22 Ab Science Aminoaryl substituted five-membered ring heterocyclic compounds for the treatment of diseases
ES2325035T3 (es) 2004-12-21 2009-08-24 Smithkline Beecham Corporation Inhibidores de quinasa erbb de 2-pirimidinil pirazolopiridina.
US7812022B2 (en) 2004-12-21 2010-10-12 Glaxosmithkline Llc 2-pyrimidinyl pyrazolopyridine ErbB kinase inhibitors
US7622583B2 (en) 2005-01-14 2009-11-24 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2
DK1838674T3 (da) 2005-01-14 2011-06-14 Chemocentryx Inc Heteroarylsulfonamider og CCR2
US20060235028A1 (en) 2005-04-14 2006-10-19 Li James J Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
JP5388574B2 (ja) 2005-05-31 2014-01-15 バーテックス ファーマシューティカルズ インコーポレイテッド イオンチャネルのモジュレーターとして有用なヘテロ環式類
UA95244C2 (ru) 2005-06-22 2011-07-25 Плексикон, Инк. Соединения и способ модулирования активности киназ, и показания для их применения
EP1899695B8 (en) 2005-06-30 2012-06-27 LED Roadway Lighting Ltd. Method and system for luminance characterization
GB0513702D0 (en) 2005-07-04 2005-08-10 Sterix Ltd Compound
WO2007009013A2 (en) 2005-07-13 2007-01-18 University Of Utah Research Foundation Methods and compositions related to a braf mutation and microsatellite stability
WO2007013997A2 (en) 2005-07-22 2007-02-01 H. Lee Moffitt Cancer Center And Research Institute Inhibition of the raf/mek/p-erk pathway for treating cancer
EP2407459A1 (en) 2005-09-27 2012-01-18 Shionogi & Co., Ltd. Synthetic intermediate in the production of a sulfonamide derivative having PGD2 receptor antagonistic activity
US7910742B2 (en) 2005-09-29 2011-03-22 Abbott Laboratories Survivin inhibitors
US7968572B2 (en) 2005-10-03 2011-06-28 Ono Pharmaceuticals Co., Ltd. Nitrogen-containing heterocyclic compound and pharmaceutical application thereof
CA2626443A1 (en) 2005-11-07 2007-05-18 Irm Llc Oxazole and thiazole ppar modulators
JP2009514964A (ja) 2005-11-07 2009-04-09 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｐｐａｒモジュレーターとしての化合物および組成物
AR056786A1 (es) 2005-11-10 2007-10-24 Smithkline Beecham Corp Compuesto de 1h- imidazo ( 4,5-c) piridin-2-ilo, composicion farmaceutica que lo comprende, procedimiento para preparar dicha composicion, su uso para preparar unmedicamento, uso de una combinacion que omprende al compuesto y al menos un agente antineoplasico para preparar un medicamento y dicha com
US20070179125A1 (en) 2005-11-16 2007-08-02 Damien Fraysse Aminopyrimidines useful as kinase inhibitors
US7625896B2 (en) 2005-11-25 2009-12-01 Hoffman-La Roche Inc. Pyridylsulfonamide derivatives
JP5103403B2 (ja) 2005-12-05 2012-12-19 スミスクライン ビーチャム コーポレーション ２−ピリミジニルピラゾロピリジンＥｒｂＢキナーゼ阻害剤
US20070135368A1 (en) 2005-12-09 2007-06-14 Knapp Pamela E Cell-to-cell transmission of siRNA induced gene silencing in mammalian cells
EP2316829A1 (en) 2005-12-21 2011-05-04 Vertex Pharmaceuticals Incorporated Heterocyclic derivatives as modulators of ion channels
WO2007084391A2 (en) * 2006-01-18 2007-07-26 Amgen Inc. Thiazole compounds as protein kinase b ( pkb) inhibitors
DK1984353T3 (en) 2006-01-23 2016-03-14 Amgen Inc Aurorakinasemodulatorer and method of use
US7560551B2 (en) * 2006-01-23 2009-07-14 Amgen Inc. Aurora kinase modulators and method of use
WO2007087429A2 (en) 2006-01-25 2007-08-02 Synta Pharmaceuticals Corp. Phenyl and pyridyl compounds for inflammation and immune-related uses
US20070219239A1 (en) 2006-02-10 2007-09-20 Mjalli Adnan M Nitrogen-containing heterocycle derivatives, pharmaceutical compositions, and methods of use thereof as antiviral agents
PE20080176A1 (es) * 2006-03-31 2008-04-25 Glaxo Group Ltd Compuestos de arilpiperazina sulfonamida como agonista de los receptores de secretagogos de la hormona de crecimiento (ghs)
US7351434B2 (en) 2006-04-07 2008-04-01 Academia Sinica Therapeutic Gastrodia extracts
EP2007716A1 (en) * 2006-04-13 2008-12-31 Glaxo Group Limited Aryl and heteroaryl sulphonamides as growth hormone secretagogue receptor agonists
JP2009534380A (ja) 2006-04-20 2009-09-24 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ｃ−ｆｍｓキナーゼインヒビター
ES2352320T3 (es) 2006-05-12 2011-02-17 Ab Science Nuevo procedimiento para la síntesis de compuestos de 2-aminoxazol.
WO2008002490A2 (en) 2006-06-23 2008-01-03 Radius Health, Inc. Treatment of vasomotor symptoms with selective estrogen receptor modulators
CN101501023A (zh) 2006-07-07 2009-08-05 贝林格尔.英格海姆国际有限公司 苯基取代的杂芳基衍生物及其作为抗肿瘤剂的用途
US20080032990A1 (en) 2006-07-07 2008-02-07 Khalifah Raja G Inhibitors of advanced glycation end products
WO2008013928A2 (en) 2006-07-28 2008-01-31 Biogen Idec Ma Inc. Treatment of cancer with interferon gene delivery in combination with a tgf-beta inhibitor
DK2054397T3 (en) 2006-08-16 2016-01-18 J David Gladstone Inst A Testamentary Trust Established Under The Will Of J David Gladstone SMALL MOLECULAR INHIBITORS OF KYNURENIN-3-MONOOXYGENASE
EP2054056A4 (en) * 2006-08-16 2010-08-25 J David Gladstone Inst A Testa SMALL MOLECULAR INHIBITORS OF KYNURENINE-3-MONOOXYGENASE
GB0622202D0 (en) 2006-11-07 2006-12-20 Addex Pharmaceuticals Sa Novel compounds
KR101472765B1 (ko) 2006-12-08 2014-12-15 밀레니엄 파머슈티컬스 인코퍼레이티드 경구용 Ｘａ 인자 억제제를 포함하는 단위 용량 제형 및 경구용 Ｘａ 인자 억제제를 사용하는 혈전증의 치료 방법
EP2125808A2 (en) 2006-12-15 2009-12-02 Bayer Schering Pharma Aktiengesellschaft 3-h-pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
JP5461197B2 (ja) 2007-02-02 2014-04-02 ベイラー カレッジ オブ メディスン 代謝障害を処置するための組成物および方法
EP2129791A4 (en) 2007-02-26 2010-07-28 Wayne John Cancer Inst BENEFITS OF THE B-RAF DNA MUTATION FOR THE DIAGNOSIS AND TREATMENT OF CANCER
EP2137158A4 (en) 2007-02-28 2012-04-18 Methylgene Inc LOW-MOLECULAR INHIBITORS OF PROTEINARGININE METHYLTRANSFERASES (PRMTS)
EP2121591A2 (en) 2007-03-08 2009-11-25 Plexxikon, Inc. Ppar active compounds
WO2008120004A1 (en) 2007-04-02 2008-10-09 Astrazeneca Ab Combination of a mek- inhibitor and a b-raf inhibitor for the treatment of cancer
WO2008129288A2 (en) 2007-04-19 2008-10-30 Boehringer Ingelheim International Gmbh Disulfonamides useful in the treatment of inflammation
PE20090288A1 (es) * 2007-05-10 2009-04-03 Smithkline Beecham Corp Derivados de quinoxalina como inhibidores de la pi3 quinasa
EP2162552A4 (en) 2007-05-11 2010-06-30 Univ Johns Hopkins BIOMARKER FOR MELANOME
CN101932580B (zh) * 2007-06-01 2013-05-22 葛兰素史密丝克莱恩有限责任公司 咪唑并吡啶激酶抑制剂
TWI519508B (zh) 2007-06-12 2016-02-01 Achaogen Inc 抗菌劑
CA2692379A1 (en) 2007-07-02 2009-01-08 Boehringer Ingelheim International Gmbh Antiproliferative compounds based on 5-membered heterocycles
WO2009010871A2 (en) 2007-07-13 2009-01-22 Addex Pharma S.A. Pyrazole derivatives as antagonists of adenosine a3 receptor
WO2009011850A2 (en) 2007-07-16 2009-01-22 Abbott Laboratories Novel therapeutic compounds
WO2009012283A1 (en) 2007-07-17 2009-01-22 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
JP2011507801A (ja) 2007-09-11 2011-03-10 ユニバーシティ オブ マサチューセッツ 癌の処置のためのインスリン様成長因子結合タンパク質７
CL2008002793A1 (es) 2007-09-20 2009-09-04 Cgi Pharmaceuticals Inc Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
US7943319B2 (en) 2007-11-09 2011-05-17 John Wayne Cancer Institute Utility of RET mutant in diagnosis and treatment of melanoma
GB0722680D0 (en) 2007-11-19 2007-12-27 Topotarget As Therapeutic compounds and their use
WO2009076140A1 (en) 2007-12-13 2009-06-18 Smithkline Beecham Corporation Thiazole and oxazole kinase inhibitors
EP2234966B1 (fr) 2007-12-18 2013-09-11 Sanofi Derives d'azetidines, leur preparation et leur application en therapeutique
WO2009096198A1 (ja) 2008-02-01 2009-08-06 Pharma Ip Limited Liability Intermediary Corporations 新規ビアリール誘導体
WO2009100214A2 (en) 2008-02-05 2009-08-13 The Johns Hopkins University Induction of thyroid iodide-handling gene expression in human cancers
JP2011511056A (ja) 2008-02-05 2011-04-07 ファイザー・インク Ｃｎｓ障害および代謝障害治療のためのピリジニルアミド
US20090275546A1 (en) 2008-04-10 2009-11-05 Istituto Superiore Di Sanita Diagnostic tests and personalized treatment regimes for cancer stem cells
US8198284B2 (en) * 2008-04-30 2012-06-12 National Health Research Institutes Treatment of neurodegenerative disorders with thiourea compounds
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
US8133884B2 (en) 2008-05-06 2012-03-13 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
CA2729767A1 (en) 2008-07-07 2010-01-14 Fasgen, Inc. Novel compounds, pharmaceutical compositions containing same, methods of use for same, and methods for preparing same
PT2324008E (pt) 2008-07-24 2012-06-25 Nerviano Medical Sciences Srl 3,4-diarilpirazoles como inibidores da proteína quinase
JP5693452B2 (ja) 2008-08-04 2015-04-01 シーエイチディーアイ ファウンデーション，インコーポレーテッド 特定のキヌレニン−３−モノオキシゲナーゼインヒビター、医薬組成物およびそれらの使用方法
WO2010018458A2 (en) 2008-08-12 2010-02-18 Crystalgenomics, Inc. Phenol derivatives and methods of use thereof
CN102216775B (zh) 2008-08-18 2014-04-16 马克斯·普朗克科学促进协会 对hsp90-抑制剂的易感性
GB0815947D0 (en) 2008-09-02 2008-10-08 Univ Dundee Compounds
US8499305B2 (en) 2010-10-15 2013-07-30 Via Technologies, Inc. Systems and methods for performing multi-program general purpose shader kickoff

Also Published As

Publication number Publication date
TW200951130A (en) 2009-12-16
EA019349B1 (ru) 2014-03-31
US20170073341A1 (en) 2017-03-16
US20090298815A1 (en) 2009-12-03
EP2282636A4 (en) 2012-06-13
HUE028820T2 (en) 2017-01-30
EP2282636A2 (en) 2011-02-16
RS54725B1 (sr) 2016-10-31
WO2009137391A3 (en) 2009-12-30
UY31806A (es) 2009-12-14
TWI432430B (zh) 2014-04-01
ZA201007960B (en) 2012-04-25
PL2282636T3 (pl) 2016-08-31
AU2009244491A1 (en) 2009-11-12
UA103319C2 (en) 2013-10-10
BRPI0912541B8 (pt) 2021-05-25
JP5426664B2 (ja) 2014-02-26
PE20091952A1 (es) 2010-01-21
BRPI0912541B1 (pt) 2021-05-11
US20110172215A1 (en) 2011-07-14
BRPI0912541A2 (pt) 2020-08-04
US9233956B2 (en) 2016-01-12
IL209018A0 (en) 2011-01-31
HK1147907A1 (zh) 2011-08-26
KR20110013456A (ko) 2011-02-09
IL209018A (en) 2015-08-31
CN102083312B (zh) 2014-08-27
US7994185B2 (en) 2011-08-09
AU2009244491B2 (en) 2014-08-07
CN102083312A (zh) 2011-06-01
MY155317A (en) 2015-09-30
JO3408B1 (ar) 2019-10-20
NZ588970A (en) 2012-06-29
HRP20160447T1 (hr) 2016-05-20
EP2282636B1 (en) 2016-03-23
DK2282636T3 (en) 2016-05-02
ES2576684T3 (es) 2016-07-08
MA32369B1 (fr) 2011-06-01
AR071617A1 (es) 2010-06-30
CA2723396A1 (en) 2009-11-12
JP2011519940A (ja) 2011-07-14
KR101628746B1 (ko) 2016-06-13
US8415345B2 (en) 2013-04-09
US20140080851A1 (en) 2014-03-20
CA2723396C (en) 2013-09-10
DOP2010000326A (es) 2010-12-15
WO2009137391A2 (en) 2009-11-12
CY1117615T1 (el) 2017-04-26
EA201001680A1 (ru) 2011-06-30
US20130144055A1 (en) 2013-06-06
US20160068523A1 (en) 2016-03-10
US8642759B2 (en) 2014-02-04
MX2010012074A (es) 2011-03-21
EP3106462A1 (en) 2016-12-21
CO6321189A2 (es) 2011-09-20
SI2282636T1 (sl) 2016-06-30
SG190624A1 (en) 2013-06-28

Similar Documents

Publication Publication Date Title
CL2009001065A1 (es) Compuestos derivados de 4-pirimidinil-1,3-tiazol (o 1,3-oxazol) sulfonamidas sustituidas, inhibidores de quinasas raf; composicion farmaceutica; procedimiento de preparacion; y uso para tratar un neoplasma susceptible, seleccionado de adenocarcinoma de barret, carcinomas del tracto biliar y cancer de seno, entre otros.
CO2020016285A2 (es) Compuestos heterocíclicos y de heteroarilo para tratar la enfermedad de huntington
EA202092001A1 (ru) Соединения для лечения болезни гентингтона
MX2021013854A (es) Compuestos para tratar enfermedad de huntington.
BR112022007612A2 (pt) Inibidores de raf quinases
MX2020014315A (es) Compuestos de heteroarilo para tratar la enfermedad de huntington.
MX391850B (es) Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington
CL2008002243A1 (es) Compuestos derivados de 2-pirazolamino-1,3,5-triazina, inhibidores de kinasa jak; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento del cancer.
EA201692285A8 (ru) Ингибиторы ezh2 для лечения лимфомы
UA122528C2 (uk) Сполуки, які модулюють fxr (nr1h4)
DOP2021000017A (es) Compuestos de pirimidina y composiciones farmaceuticas para prevenir o tratar cánceres que incluyen los mismos
BR112015011760A2 (pt) composto, uso do composto, e uso de uma composição farmacêutica
MX372716B (es) Nuevos derivados hidroxiéster, un proceso para su preparación y composiciones farmacéuticas que los contienen.
BR112012016797A2 (pt) intensificador dinâmico de baixo utilizando compressor com equalizador incorporado
CL2008002430A1 (es) Compuestos derivados de bencenosulfonamida, inhibidores de catepsina c; composicion farmaceutica que los comprende; y su uso para el tratamiento de la epoc.
CL2008000862A1 (es) Compuestos derivados de triazolonas, inhibidores no nucleosidos de transcriptasa inversa; composicion farmaceutica que contiene a dichos compuestos; y uso del compuesto para tratar la infeccion del vih-1.
UY31215A1 (es) Compuestos de morfolino pirimidina, procesos para su preparacion, composiciones farmacéuticas conteniéndolos y su uso en terapia.
MX2019012847A (es) Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer.
CL2007002382A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento del cancer a la piel.
EA201891440A1 (ru) Составы/композиции, содержащие ингибитор btk
EA201070327A1 (ru) Катехоламиновые производные и их пролекарства
UY29360A1 (es) Nuevos derivados de pirazol, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones.
MX2018008772A (es) Formulaciones/composiciones que comprenden un inhibidor de btk.
CL2008000202A1 (es) Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor.
CL2021001753A1 (es) Compuestos derivados de 2,4-diaminoquinazolina; composición farmacéutica; y su uso para el tratamiento de una infección vírica, cáncer, entre otras (divisional de solicitud 202002253).